Why ImmunoGen Inc. Shares Roared Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of ImmunoGen -- an anticancer therapeutics company that develops in-house and partnered compounds utilizing its targeted antibody payload technology -- soared by as much as 14% after announcing a collaborative licensing agreement with Novartis .
So what: According to ImmunoGen's press release today, ImmunoGen's granted Novartis a license to use its proprietary TAP technology for the study of an unspecified cancer target. This would mark the third such collaborative agreement between Novartis and ImmunoGen and the fifth large licensing deal ImmunoGen has struck just this year with big pharmaceutical companies. ImmunoGen also notes that the terms for this licensing agreement were consistent with the agreement announced exactly one month ago today with Novartis whereby it receives an upfront payment and has the ability to earn up to another $200 million in royalties.
Now what: This is precisely the sort of pick-me-up that shareholders needed after ImmunoGen shelved its most advanced in-house therapy, IMGN901, last week. One thing to remember about ImmunoGen and its proprietary TAP technology is that it does have an approved drug already on the market in Kadcyla. Therefore, the efficacy of its technology isn't so much in question anymore, which lends itself to multiple collaborative and licensing opportunities. It's for this reason -- as well as its more than one dozen combined in-house and partnered trials that are ongoing -- that I feel ImmunoGen needs to remain a biotech you watch very closely!
A high growth stock to rival ImmunoGen
ImmunoGen's expansive pipeline offers plenty of potential -- but so does this incredible tech stock -- which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!
The article Why ImmunoGen Inc. Shares Roared Higher originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool recommends ImmunoGen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
